Xilio Therapeutics, Inc.
XLO
$0.755
$0.00140.19%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 8.08M | 2.93M | 1.72M | 2.26M | 2.36M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 8.08M | 2.93M | 1.72M | 2.26M | 2.36M |
| Cost of Revenue | 15.33M | -- | -- | -- | 11.22M |
| Gross Profit | -7.25M | 2.93M | 1.72M | 2.26M | -8.86M |
| SG&A Expenses | 7.12M | 8.52M | 6.52M | 6.31M | 5.82M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.45M | 16.78M | 15.35M | 17.07M | 17.03M |
| Operating Income | -14.37M | -13.85M | -13.63M | -14.80M | -14.67M |
| Income Before Tax | -15.84M | -13.27M | -13.09M | -14.02M | -13.93M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -15.84M | -13.27M | -13.09M | -14.02M | -13.93M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.84M | -13.27M | -13.09M | -14.02M | -13.93M |
| EBIT | -14.37M | -13.85M | -13.63M | -14.80M | -14.67M |
| EBITDA | -13.99M | -13.35M | -13.25M | -14.42M | -14.23M |
| EPS Basic | -0.31 | -0.18 | -0.20 | -0.22 | -0.32 |
| Normalized Basic EPS | -0.19 | -0.11 | -0.13 | -0.14 | -0.20 |
| EPS Diluted | -0.31 | -0.18 | -0.20 | -0.22 | -0.32 |
| Normalized Diluted EPS | -0.19 | -0.11 | -0.13 | -0.14 | -0.20 |
| Average Basic Shares Outstanding | 51.83M | 74.70M | 64.68M | 63.47M | 43.95M |
| Average Diluted Shares Outstanding | 51.83M | 74.70M | 64.68M | 63.47M | 43.95M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |